Latest Stock Buy or Sell? Make More Informed Decisions!
Today, The Panic-Proof Portfolio (Stockchase Research) and Gordon Reid commented about whether QCOM-Q, JPM-N, JEC-N, CCL-N, GE-N, T-N, TSLA-Q, GM-N, PLTR-Q, RBC-N, FDX-N, CSCO-Q, RTX-N, GD-N, LMT-N, JNJ-N, BAC-N, AAPL-Q, DIS-N, CVS-N, ABT-N, CRMT-Q, WMK-N, D.UN-T, SAH-N, LZB-N are stocks to buy or sell.
- Page 1/2
- Next Page
Premium content
TOP PICK
Stockchase Research Editor: Michael O'Reilly Recently reported earnings showed sales rebounding, revenue growth and a positive outlook from management -- meeting, but not beating analyst expectations. Management expects sales growth exceeding 30% next quarter, compared to the pandemic impact a year ago. Cash flow is estimated to have increased by over $230 million over the year and with virtually no debt the company is well positioned. It pays a decent dividend, backed by a 21% payout ratio. We would buy this with a stop-loss at $29, looking to achieve $47.50 -- upside of 25%. Yield 1.59% (Analysts’ price target is $47.50)
Consumer Products
Premium content
TOP PICK
Stockchase Research Editor: Michael O'Reilly SAH operates car dealerships. Its EchoPark used car business has benefitted from the pandemic, where sales were up 25% over the year and prices rose. They have plans to expand this segment further. New car dealerships held steady as lower volumes were offset by higher prices as well. Margins overall hit a record high at 68%, allowing EPS to beat expectations, up 52% on the year. It pays a small dividend backed by an expected payout ratio of 15% of cash flow. We would buy this with a stop-loss at $30, looking to achieve $51.50 -- 35% potential upside. Yield 0.97% (Analysts’ price target is $51.14)
Automotive
Premium content
TOP PICK
Stockchase Research Editor: Michael O'Reilly D.UN has survived the ravages of the pandemic, it pays an excellent dividend, backed by a 23% payout ratio of cashflow. Trading at 4.5x times earnings and 66% of book, it is good value here. As vaccinations increase and workplaces begin to reopen, this will continue to thrive. We would buy this with a stop-loss at $16, looking to achieve $25 -- upside potential of 28%. Yield 5.18% (Analysts’ price target is $24.96)
property mngmnt
investment
Premium content
PAST TOP PICK
Premium content
PAST TOP PICK
(A Top Pick Nov 17/20, Up 27.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CRMT has achieved its $134 target. To be disciplined, we recommending covering 50% of the position and trailing up the stop (from $85) to $120. This would all but guarantee an minimum investment return of 21%.
Automotive
Premium content
PAST TOP PICK
(A Top Pick Oct 08/20, Up 17.8%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has achieved its $128 objective. To be disciplined, we recommend covering 50% of the position and trailing up the stop (from $97) to the original recommended price level at $109.
biotechnology
pharmaceutical
COMMENT
Are you still finding reasonably priced equities? We are. You can't look just at valuations. You have to look at the surrounding environment. Historically low interest rates, which naturally lead to higher valuations. Lower cost of capital, as well as competing asset classes. On top of that, the Fed has the market's back. Big cap has really been leading, driving markets higher. A lot of companies under the hood have good valuations, in different sectors, more value oriented, more cyclical, and that's where the economy is going.
COMMENT
Are you interested in stocks that have been hurt by the pandemic? Not necessarily, because the market also has been sniffing around there and driven prices higher. Look at DIS, MCD, and BKNG. He's seeing more value in the likes of GM, an industrial that represents great value with great innovation ahead of it.
HOLD
A real health conglomerate. Vertically integrated. Inexpensive valuation, at less than 10x. Recent earnings moved the needle down. Market may have been disappointed on 2021 guidance. 12.5% free cashflow yield. An excellent opportunity. The vaccine rollout will be a major contributor to its financial success.
specialty stores
DON'T BUY
DON'T BUY
LMT vs. GD vs. RTX When analyzing a company, you also want to analyze its peers. This is the case here. Instead, look at General Dynamics. They acquired CSRA, entrenched in cyber defense, and this is where corporate and government money will be invested. Also see Raytheon, a hybrid of a commercial application with a defense contractor. RTX has great promise, undervalued, considerable cashflow in the future.
Transportation
BUY
GD vs. LMT vs. RTX When analyzing a company, you also want to analyze its peers. This is the case with Lockheed Martin. Instead, look at General Dynamics. They acquired CSRA, entrenched in cyber defense, and this is where corporate and government money will be invested. Also see Raytheon, a hybrid of a commercial application with a defense contractor. RTX has great promise, undervalued, considerable cashflow in the future.
transportation equip & components
